TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients were 16 to 50 years of age;~* had received a diagnosed of schizophrenia in accordance with criteria set out in the Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV);~* were confirmed to be clinically stable by the investigator (the total score ≤60 on the Positive and Negative Syndrome Scale \[PANSS\] or a decrease of fifty percent from acute period in the total score on PANSS)~* and taken maintenance treatment with any one of the following seven oral antipsychotics:~  * chlorpromazine~ * sulpiride clozapine~ * risperidone~ * olanzapine~ * quetiapine~ * aripiprazole~Exclusion Criteria:~* Patients were excluded if they had received a diagnosis of schizoaffective disorder, mental retardation, or other cognitive disorders;~* had a history of serious adverse reactions to the proposed treatment;~* were pregnant or breastfeeding; or had a serious and unstable medical condition.~* Patients were excluded if they were unable to provide informed consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): the comparator arm will only receive one of the seven antipsychotic
- 2 (Type: EXPERIMENTAL): the experimental group will receive one of the seven study drugs combination with psychosocial intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 5 - 60 years old~* Fever (axillary temperature equal or higher than 37,5 °C) or history of fever in the previous 24 hours~* Monoinfection with P. falciparum, with parasitic density between 1,000 and 200,000 par/µl~* Informed consent provided by patient or parent or legal tutor~  • Exclusion criteria:~* Mixed malaria infection~* Pregnancy or breastfeeding to child ≤ 6 months of age~* One or more danger signs or any sign of severe or complicated malaria~* A concomitant severe disease~* History of treatment with mefloquine in the last 60 days or chloroquine, primaquine or quinine within the 14 days before the present episode~* History of neuropsychiatric disease~* History of hypersensitivity reactions to artemisinins or mefloquine~* History of splenectomy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dihydroartemisin-piperaquine (Type: EXPERIMENTAL): Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
- Mefloquine + Artesunate (MAS3) (Type: ACTIVE_COMPARATOR): The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current HAM-D score of ≥ 20~* Patients with severe asthma (defined as asthma requiring three or more course of oral corticosteroids in the past year).~* No changes in asthma medications, oral corticosteroid use, or treatment for respiratory tract infections in the past week~* Needs to have taken ≥ 3 courses of oral corticosteroids, for asthma, in the past 12 months.~* Both male and female~* English- or Spanish-speaking~Exclusion Criteria:~* Current substance or alcohol abuse/dependence~* MDD with psychotic features (delusions, hallucinations, disorganized thought processes)~* Bipolar disorder~* Schizophrenia or schizoaffective disorder~* Substance-induced mood disorder and mood disorder secondary to a general medical condition~* Mental retardation or other severe cognitive impairment~* Prison or jail inmates~* Pregnant or nursing women or women of childbearing age who will not use The University of Texas Southwestern Medical Center - Institutional Review Board (UTSW IRB) approved methods of birth control or abstinence during the study~* Treatment-resistant depressed persons defined as having failed two adequate trials of antidepressants~* Current antipsychotic or antidepressant therapy or psychotherapy~* Initiation of other psychotropic medications or psychotherapy within past 2 weeks (e.g., anxiolytics, hypnotics)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Matching Escitalopram given orally daily (for a 12-week duration).
- Escitalopram (Type: ACTIVE_COMPARATOR): Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Outpatient at least 12 years of age with a diagnosis of asthma at least 12 weeks prior to first visit~* Both genders; females of child bearing potential must be willing to use appropriate contraception during the study~* Pre-bronchodilator FEV1 of at least 60% predicted~* FEV1 reversibility of at least 12% and 200ml~* Current asthma therapy that includes a non-corticosteroid controller and/or short acting beta-agonist~Exclusion Criteria:~* History of life-threatening asthma exacerbation with the past 10 years~* Asthma exacerbation requiring oral corticosteroids within the past 3 months or overnight hospital stay within the past 6 months~* Current or recent respiratory infection or current oral candida infection~* Presence of a significant respiratory disease or other medical condition that is uncontrolled or that could affect subject safety or study outcome~* Known or suspected allergy to study medication or materials~* Taking another investigational medication or prohibited medication during the study~* Current smokers or former smokers with significant tobacco exposure~* Previous treatment with fluticasone furoate in a phase II or III study~* Children in Care

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone furoate 50 mcg (Type: EXPERIMENTAL): Once daily inhalation powder via Novel Dry Powder Inhaler
- Fluticasone propionate 100mcg (Type: ACTIVE_COMPARATOR): Twice daily inhalation powder via DISKUS/ ACCUHALER
- Placebo (Type: PLACEBO_COMPARATOR): Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or a female (not pregnant and agreeable to take birth control measures until one month after study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results~* Are nonsmokers, have not smoked for at least 6 months prior to entering the study~Exclusion Criteria:~* Are currently participating in or completed a clinical trial within the last 30 days~* Have previously participated or withdrawn from this study~* Have donated blood or have blood loss of more than 500 mL within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 (Type: EXPERIMENTAL): Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
- Insulin Lispro (Humalog) (Type: ACTIVE_COMPARATOR): Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Age \>= 18 years at screening(visit 1A) but \<= 80 years Signed and dated written informed consent in accordance with good clinical practice and local legislation prior to admission to the trial Diagnosis of ischemic stroke with a measureable neurological deficit on National Institute of Health Stroke Scale (NIHSS) Thrombolytic therapy can be initiated within 3 to 4.5 hours of stroke onset Further inclusion criteria apply~Exclusion criteria:~Evidence of intracranial haemorrhage (ICH) on the (Computer Tomography) CT/(Magnetic Resonance Imaging)MRI-scan or symptoms suggestive of subarachnoid haemorrhage, even if the CT/MRI-scan is normal Acute bleeding diathesis Severe stroke as assessed clinically( e.g. National Institute of Health Stroke Scale\>25) and/ or imaging demonstrates multi-lobar infarction (hypodensity \>1/3 cerebral hemisphere) Severe uncontrolled arterial hypertension, e.g. systolic blood pressure\>185 mmHg or diastolic blood pressure\>110mmHg, or aggressive management (intravenous medication) necessary to reduce blood pressure to these limits Blood glucose \<50mg/ dL or \>400 mg/dL Any history of prior stroke in previous 3 months, or any history of prior stroke with concomitant diabetes Seizure at stroke onset Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- alteplase (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. healthy male subjects~Exclusion criteria:~1. Any relevant deviation from healthy conditions

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 Nintedanib (Reference) (Type: EXPERIMENTAL): single dose, oral with 240 ml water
- 2 Nintedanib + Ketoconazole (Test) (Type: EXPERIMENTAL): Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
- 3 Nintedanib (Reference) (Type: EXPERIMENTAL): single dose, oral with 240 ml water
- 4 Nintedanib + Ketoconazole (Test) (Type: EXPERIMENTAL): Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria~* Active PsA defined as the presence of at least 3 (out of 68) tender and at least 3 (out of 66) swollen joints~* Presence of active plaque psoriasis with a BSA ≥3%~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)~Exclusion Criteria:~* Current or prior use of biologic agents for treatment of Ps or PsA~* Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA~* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than psoriatic arthritis~* Serious infection within the last 3 months~* Active Crohn's disease or active ulcerative colitis~* Active vasculitis or uveitis~* Diagnosis of or history of malignant disease \<5 years prior to randomization~* Women who are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps.
- Adalimumab (Type: ACTIVE_COMPARATOR): 80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.~2. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~3. Women aged 18 years to 40 years.~4. Diagnosed with HIV infection.~5. Medically eligible for the etonogestrel subdermal implant as a contraceptive method.~6. Receiving efavirenz-based anti-retroviral therapy for a minimum of 3 months prior to screening.~7. Must agree to have concurrent highly effective non-hormonal contraception with a copper intrauterine device, if not previously medically sterilized.~8. Participants must report regular menses (bleeding for 4-8 days at 21- to 35-day intervals) for the preceding 2 months.~9. Participants must have a negative urine pregnancy test at entry and report no unprotected sex since the last menstrual period or in the last two weeks.~Exclusion Criteria:~1. HIV RNA \> 50 copies/mL at screening visit.~2. Serum hemoglobin \< 10.0 g/dL.~3. Elevations in serum levels of alanine transaminase above 5 times the upper limit of normal.~4. Elevations in serum creatinine above 2.5 times the upper limit of normal.~5. Use of drugs known to be contraindicated with etonogestrel or efavirenz within 30 days of study entry. Due to the dynamic nature of drug interactions related to antiretroviral therapy, the study team will review all concomitant medications at screening for drug interactions with efavirenz and the etonogestrel implant.~6. Currently pregnant or postpartum less than 30 days at study entry.~7. Breastfeeding women within 6 months of delivery.~8. Use of hormonal contraception in the preceding 3 months prior to entry~9. Participants determined to be ineligible for intrauterine device placement.~10. Patients with a history of hypersensitivity to etonogestrel implant, undiagnosed vaginal bleeding, diagnosed or suspected sex hormone dependent neoplasia, benign or malignant liver tumor, or thromboembolic disease.~11. Presence of any active clinically significant disease or life-threatening disease that, in the investigator's opinion, would compromise the subject's safety or outcome of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Standard Dose Etonogestrel Implant (Type: ACTIVE_COMPARATOR): Single 68 mg etonogestrel implant
- Increased Dose Etonogestrel Implant (Type: EXPERIMENTAL): Two 68 mg (136 mg total) etonogestrel implants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Must satisfy A and B and C below:~A. Women aged 45+~B. Postmenopausal~C. Osteoporotic with high risk of fracture~Exclusion Criteria:~* History of significant hepatic, renal, cardiovascular, malignant disease, or conditions with impaired immune system~* Current alcohol or substance abuse~* Major psychiatric disorders~* Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia~* Known congenital or acquired bone disease other than osteoporosis~* Current use or past use in the past 12 months of oral bisphosphonates~* Current use or use in the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin~* Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months~* Any current or previous use of strontium or intravenous bisphosphonates~* Sensitivity to cell-derived drug products or teriparatide~* Extensive dental work involving dental extraction or dental implant within the past 2 months or in the upcoming 2 months~* Inability to sit upright for 30 minutes~* Esophageal abnormalities

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Denosumab 60mg subcutaneous injection (Type: ACTIVE_COMPARATOR): Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
- Alendronate 70mg weekly x 8 weeks (Type: ACTIVE_COMPARATOR): Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* CKD stage 1 patients~* Older than 18 years of age~* Type 2 Diabetic patients~* Proteinuria~* Hypertension~Exclusion Criteria:~* History of coronary artery disease~* Smokers~* Taking statins or renin-angiotensin blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Amlodipine (Type: EXPERIMENTAL): None
- Valsartan (Type: EXPERIMENTAL): None
- Valsartan+Amlodipine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete